(News Bulletin 247) – The Biosenic study devoted to the healing of difficult fractures gave negative results, thus leading to a suspension of the trial, the biotechnology company announced on Monday.
The former Bone-Therapeutics – specializing in cell repair – justifies its decision by the fact that its interventional study around ALLOB, its flagship product, did not reach the main endpoint of the phase IIb trial.
The objective of this study was to evaluate the effectiveness of administering ALLOB, a derivative of mesenchymal stem cells, immediately after a complicated bone fracture, in order to accelerate healing.
Unlike the previous successful phase, the early application of ALLOB did not accelerate the healing process, Biosenic says.
The title thus lost more than 26% on Euronext Paris late Monday morning.
Following this failure, BioSenic plans to focus its resources on its most promising and advanced asset, Medsenic’s OATO platform for autoimmune diseases.
The company will thus be able to focus on the advanced phase III trial of oral arsenic trioxide, targeting chronic graft versus host disease, which is the subject of an ongoing procedure with the American FDA. .
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
